Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Added to Ongoing Metformin Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Alone
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
OBJECTIVE—The efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, added to ongoing metformin therapy, were assessed in patients with type 2 diabetes who had inadequate glycemic control (HbA1c [A1C] ≥7 and ≤10%) with metformin alone. RESEARCH DESIGN AND METHODS—After a screening diet/exercise run-in period, a metformin dose titration/stabilization period, and a 2-week, single-blind, placebo run-in period, 701 patients, aged 19–78 years, with mild to moderate hyperglycemia (mean A1C 8.0%) receiving ongoing metformin (≥1,500 mg/day) were randomly assigned to receive the addition of placebo or sitagliptin 100 mg once-daily in a 1:2 ratio for 24 weeks. Patients exceeding specific glycemic limits were provided rescue therapy (pioglitazone) until the end of the study. The efficacy analyses were based on an all-patients-treated population using an ANCOVA and excluded data obtained after glycemic rescue. RESULTS—At week 24, sitagliptin treatment led to significant reductions compared with placebo in A1C (−0.65%), fasting plasma glucose, and 2-h postmeal glucose. Fasting insulin, fasting C-peptide, fasting proinsulin-to-insulin ratio, postmeal insulin and C-peptide areas under the curve (AUCs), postmeal insulin AUC–to–glucose AUC ratio, homeostasis model assessment of β-cell function, and quantitative insulin sensitivity check index were significantly improved with sitagliptin relative to placebo. A significantly greater proportion of patients achieved an A1C <7% with sitagliptin (47.0%) than with placebo (18.3%). There was no increased risk of hypoglycemia or gastrointestinal adverse experiences with sitagliptin compared with placebo. Body weight decreased similarly with sitagliptin and placebo. CONCLUSIONS—Sitagliptin 100 mg once-daily added to ongoing metformin therapy was efficacious and well tolerated in patients with type 2 diabetes who had inadequate glycemic control with metformin alone.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, studies report an increased incidence of nasopharyngitis in subjects randomly assigned to DPPIV inhibitor 35,38,40 ; in 1 study, 1 of 175 sitagliptin-treated subjects was hospitalized for angioedema.41”
From Dipeptidyl Peptidase IV in Angiotensin-Converting Enzyme Inhibitor–Associated Angioedema (2008) · cites this paper as [40]
Citations
Cites
MENTLEIN, R., GALLWITZ, B., & SCHMIDT, W. E. (1993) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1993.tb17986.x · Cited by 1,161
Oral Antihyperglycemic Therapy for Type 2 Diabetes: Scientific Review
Inzucchi, S. E. (2002) · JAMA · doi:10.1001/jama.287.3.360 · Cited by 1,065
Kim, D., Wang, L., Beconi, M., Eiermann, G. J., Fisher, M. H., He, H., Hickey, G. J., Kowalchick, J. E., Leiting, B., Lyons, K., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0493156 · Cited by 822
Deacon, C. F., Johnsen, A. H., & Holst, J. J. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.80.3.7883856 · Cited by 792
Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans
Holst, J. J., & Gromada, J. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00545.2003 · Cited by 611
Standards of Medical Care for Patients With Diabetes Mellitus
American Diabetes Association (2003) · Diabetes Care · doi:10.2337/diacare.26.2007.s33 · Cited by 609
HERMAN, G., STEVENS, C., VANDYCK, K., BERGMAN, A., YI, B., DESMET, M., SNYDER, K., HILLIARD, D., TANEN, M., & TANAKA, W. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.09.002 · Cited by 519
Herman, G. A., Bergman, A., Stevens, C., Kotey, P., Yi, B., Zhao, P., Dietrich, B., Golor, G., Schrodter, A., Keymeulen, B., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1009 · Cited by 495
Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes.
Holst, J. J., & Deacon, C. F. (1998) · Diabetes · doi:10.2337/diabetes.47.11.1663 · Cited by 487
Pospisilik, J. A., Martin, J., Doty, T., Ehses, J. A., Pamir, N., Lynn, F. C., Piteau, S., Demuth, H.-U., McIntosh, C. H. S., & Pederson, R. A. (2003) · Diabetes · doi:10.2337/diabetes.52.3.741 · Cited by 332
Cited by
Items 701–785 of 785
Standards of Care and the Burden of Treatment Failure in Type 2 Diabetes
Urquhart, S. (2007) · JAAPA · doi:10.1097/01720610-200710000-00006
Leiva, A., Varas, P., Amigo, L., Contreras‐Duarte, S., Alberto Maiz, G., & Rigotti, A. (2010) · Revista chilena de cardiología · doi:10.4067/s0718-85602010000300009
Combination Therapy in Type 2 Diabetes
Bae, H. Y. (2011) · The Korean Journal of Internal Medicine
Dipeptidyl Peptidase‐4 Inhibitors
Barnett, A. H., & Grice, J. (2011) · Wiley eBooks · doi:10.1002/9781118682197.ch5
Welcome Reassurance About GLP-1 Drugs—But They Are Still Young and Not Fully Grown
Riddle, M. C. (2015) · Diabetes Care · doi:10.2337/dc14-2649
Sitagliptyna — nowoczesny lek w terapii cukrzycy typu 2
Kujawska-Łuczak, M., & Pupek‐Musialik, D. (2011) · Forum Zaburzeń Metabolicznych
Lonati, F., Magoni, M., Cecchi, D., Medea, G., Rossi, A., Indelicato, A., & Scarcella, C. (2008)
Effect of Alogliptin, a DPP-4 Inhibitor, on Markers of Lipid Metabolism in Type 2 Diabetic Patients
Kishitani, Y. (2014) · International Journal of Diabetes and Clinical Research · doi:10.23937/2377-3634/1410017
Role of DPP IV Inhibitor in Type-2 Diabetes Mellitus
Chakraborty, A. K., & Patil, U. K. (2013)
Clinical Use of Incretin-Based Therapy in Type 2 Diabetes Mellitus
Shomali, M. E. (2011)
Diabetes in China 3 Early therapy for type 2 diabetes in China
Yang, W., & Key, G. P. (2014)
García Ramos, G., & Cristina, I. (2008)
Unit 5. Antidiabetic treatment options
Aye, M. M., & Jennings, P. (2011) · Practice Nursing · doi:10.12968/pnur.2011.22.8.cpd8
La terapia del diabete mellito tipo 2 basata sulle incretine
Prato, S. D., Sesti, G., Bonora, E., Bosi, E., Consoli, A., Cucinotti, D., Ghirlanda, G., Giorgino, F., Lauro, D., Marchetti, P., et al. (2008) · CINECA IRIS Institutial research information system (University of Pisa)
Extrapancreatic actions of incretin-based therapies on bone in diabetes mellitus
Mansur, S. A. (2015) · UTHM Institutional Repository (Universiti Tun Hussein Onn Malaysia)
Dipeptidyl-Peptidase IV inhibitors and glycemic control in type 2 Diabetes Mellitus
Sapkota, L. B., & Thapa, S. (2016) · Journal of College of Medical Sciences-Nepal · doi:10.3126/jcmsn.v12i1.14684
Insulin Treatment in Managing Type 2 Diabetes: Challenges and Opportunities
Leahy, J. L. (2007) · JAAPA · doi:10.1097/01720610-200710000-00007
Sitagliptin — A New Oral Agent for Diabetes
Brett, A. S. (2007) · Journal watch · doi:10.1056/jw200701020000002
Bayón, C., Araceli, B. M., & de León, L. F.-D. (2010)
Novel Approaches to Diabetes Treatment
Hopkins, M. (2007) · Canadian Pharmacists Journal / Revue des Pharmaciens du Canada · doi:10.1177/171516350714000122
Dipeptidyl Peptidase-4 Inhibition – Advances in our Understanding of Diabetes Management
Deacon, C. F., Holst, J. J., & Lecturer, S. (2008) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2008.04.02.47 · Cited by 1
The Role of Incretins in Insulin Secretion
Salehi, M. (2016) · Springer eBooks · doi:10.1007/978-3-319-20797-1_4-1
Vik, K. H. (2010) · NORA - Norwegian Open Research Archives · Cited by 2
Incretins, Incretinmimetics, Inhibitors (2 nd part)
Bayón, C., Araceli, B. M., & de León, L. F.-D. (2010)
GI Peptides, Energy Balance, and Cancer
Bruno, D. S., & Wolfe, M. M. (2016) · Energy balance and cancer · doi:10.1007/978-3-319-41677-9_11
Sitagliptin Review of its Use in the Management of Type 2
Åhrén, B., Barnett, A. H., Eriksson, J. G., Mohan, V., Nilsson, P. M., Raz, I., & Yeap, B. B. (2010)
Rola leków inkretynowych w leczeniu cukrzycy typu 2
Mizerski, G., & Jaroszyński, A. (2011) · Family Medicine & Primary Care Review
Dipeptidyl-peptidase IV inhibitors and glycemic control in type 2 diabetes mellitus
Sapkota, L. B., & Thapa, S. (2017) · Journal of Chitwan Medical College · doi:10.3126/jcmc.v6i1.16656
Pharmacology of Dipeptidyl Peptidase-4 Inhibitors and Differences
Baetta, R., & Corsini, A. (2011)
El efecto incretina y su participación en la diabetes mellitus tipo 2
Cuauhtémoc, C., & León, N. (2010)
Pharmacological control of blood sugar
Tarigopula, G., & Davies, M. J. (2011) · Anaesthesia & intensive care medicine · doi:10.1016/j.mpaic.2011.07.012
Kristin, E. (2017) · Journal of the Medical Sciences (Berkala Ilmu Kedokteran) · doi:10.19106/jmedsci004903201706
Vascular Adverse Events Associated with Sitagliptin Agent in Taiwan: A Drug Evaluation Report
Yen, Y.-H. (2018) · Biomedical Journal of Scientific & Technical Research · doi:10.26717/bjstr.2018.02.000815
Sitagliptin Monoterapisi ile Kombinasyon Tedavilerinin Karşılaştırılması
Gül, Ö. Ö., Şişman, P., Cander, S., & Ersoy, C. (2018) · Uludağ Üniversitesi Tıp Fakültesi Dergisi · doi:10.32708/uutfd.480706
New pharmacological approaches in type 2 diabetes mellitus
Cusi, K. J. (2009) · Dialnet (Universidad de la Rioja) · doi:10.1016/b978-84-8086-683-5.50016-0
Diabetes mellitus and DPP IV/CD26 Inhibitors
Batičić, L., Detel, D., Varljen, J., Pugel, E. P., Grčić, A., & Ivanović, L. (2019) · Medicina Fluminensis · doi:10.21860/medflum2019_221600 · Cited by 1
Can, Ö., Kı̇şı̇oğlu, S. V., Tekin, S., & Sargin, M. A. (2019) · Ankara Medical Journal · doi:10.17098/amj.624529
Yoshikawa, F., Uchino, H., Nagashima, T., Usui, S., Miyagi, M., Ando, Y., Kumashiro, N., & Hirose, T. (2020) · Preprints.org · doi:10.20944/preprints202002.0124.v1
Thérapeutique des désordres glycémiques
Monnier, L., & Colette, C. (2014) · Elsevier eBooks · doi:10.1016/b978-2-294-73954-5.00007-x
Thérapeutique des désordres glycémiques
(2010) · Elsevier eBooks · doi:10.1016/b978-2-294-70868-8.50007-4
Maniyar, Y. A., & Bidarurmath, S. C. (2021) · PARIPEX-INDIAN JOURNAL OF RESEARCH · doi:10.36106/pijr/2900329
Oh, J. Y. (2011) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2011.35.3.298
오승준 (2011)
Efficacy and Safety of Sitagliptin in Type 2 Diabetic Libyan patients
Etaher, N. A., Saeed, N. M., Aween, H. I., Elajam, M. A., & Sherif, F. M. (2021) · South Asian Research Journal of Medical Sciences · doi:10.36346/sarjms.2021.v03i01.003
Hussain, S., Mustafa, A., Mumtaz, A., Shaheen, G., Qaiser, F., & Soban, M. (2021) · Pakistan Journal of Medical and Health Sciences · doi:10.53350/pjmhs2115102800
Non-insulin agents in the management of type 2 diabetes
Fonseca, V. A., Pendergrass, M., & McDuffie, R. H. (2009) · Springer eBooks · doi:10.1007/978-1-84882-103-3_3
Singh, R., Rao, H. K., Sharma, A. K., Singh, T. G., Parashar, A., Singh, R., & Saini, B. (2021) · Serbian Journal of Experimental and Clinical Research · doi:10.2478/sjecr-2021-0057 · Cited by 1
(2021) · American Journal of PharmTech Research · doi:10.46624/ajptr.2021.v11.i5.009
Incretin Enhancers, Incretinomimetics – from Therapeutic Concept to Clinical Application
Winkler, G. (2007) · Hungarian Medical Journal · doi:10.1556/oh-hmj.2007.28093
Current literature in diabetes
(2007) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.760
The Role of Incretins in Insulin Secretion
Salehi, M. (2017) · Springer eBooks · doi:10.1007/978-3-319-18741-9_4
Thérapeutique des désordres glycémiques
(2019) · Elsevier eBooks · doi:10.1016/b978-2-294-75889-8.00007-5
Current awareness: Pharmacoepidemiology and drug safety
(2007) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1378
Glucagon and the Glucagon-Like Peptides
Drucker, D. J. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-5583-9.00035-6
Sitagliptin/metformin fixed-dose combination: a guide to its use in type 2 diabetes mellitus
&NA; (2011) · Drugs & Therapy Perspectives · doi:10.2165/11207830-000000000-00000
(2008) · Australian Prescriber · doi:10.18773/austprescr.2008.028
(2008) · Australian Prescriber · doi:10.18773/austprescr.2008.031
Challenges in the Management of Type 2 Diabetes in the Elderly
Horton, E. S. (2007) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2007.00.02.41
(2015) · Elsevier eBooks · doi:10.1016/b978-0-444-53717-1.01717-0
INSULINS AND OTHER HYPOGLYCEMIC DRUGS
(2009) · Elsevier eBooks · doi:10.1016/b978-0-444-53271-8.50008-9
(2008) · Australian Prescriber · doi:10.18773/austprescr.2008.029
(2008) · Australian Prescriber · doi:10.18773/austprescr.2008.032
Masche, U. (2007) · pharma-kritik · doi:10.37667/pk.2007.176
(2008) · Australian Prescriber · doi:10.18773/austprescr.2008.030
R, P. R. P., Brigida, S., Elizabeth, A. A., G, S. G. S., & Lella, T. (2022) · Biomedical & Pharmacology Journal · doi:10.13005//bpj/2431
Khan, A., Kanpurwala, M. A., Khan, R. A., Mahmudi, N. F., Lohano, V., Ahmed, S., Khan, M., Uddin, F., Ali, S. M., Saghir, M., et al. (2023) · BMC Endocrine Disorders · doi:10.1186/s12902-023-01492-2
Kumar, K. V. S. H., Godbole, S. V., Farishta, F., Damodharan, S., Chafekar, D. S., Bafna, A. A., Iyer, R., Sugumaran, A., & Mohanasundaram, S. (2024) · International Journal of Diabetes and Technology · doi:10.4103/ijdt.ijdt_39_24
Mohanty, I. R., Dhanawane, U., & Tiwari, D. D. (2025) · Natural Product Research · doi:10.1080/14786419.2025.2472283
Yabe, D., Hamamoto, Y., Kawanami, D., Nishimura, R., Terauchi, Y., Amadid, H., Braae, U. C., Major‐Pedersen, A., & Suzuki, R. (2025) · Journal of Diabetes Investigation · doi:10.1111/jdi.70099 · Cited by 2
Lee, H., Lee, M., Park, Y. K., & Lee, J. (2025) · Journal of the Korean Society of Food Science and Nutrition · doi:10.3746/jkfn.2025.54.9.723
Fricke, U., & Schwabe, U. (2008) · Springer eBooks · doi:10.1007/978-3-540-69219-5_2 · Cited by 1
Chu, L., Cai, X., Yang, W., Lv, F., Nie, L., & Ji, L. (2020) · Figshare · doi:10.6084/m9.figshare.13240350
Prasad, S., Ahuja, A., Sharma, S., Nagda, J., Agrawal, S., Parmar, V., & Vardhan, H. (2026) · Cardiovascular Diabetology – Endocrinology Reports · doi:10.1186/s40842-026-00296-2
Process Design of High-Yield Sitagliptin Phosphate Tablets Workshop
何, 丽. (2026) · Hans Journal of Biomedicine · doi:10.12677/hjbm.2026.163059
Sil, P., Tiwari, R., Garisetti, V., Baskaran, S. P., Dhanaseelan, F. H., Srivastava, S., & Samal, A. (2026) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2026.109194 · Cited by 3
Medabalimi, M., Kasimedu, S., & Satyanarayana, S. V. (2026) · AIP conference proceedings · doi:10.1063/5.0288296
Janež, A., Bojić, M., Božek, T., Kamenov, Z. A., Milenković, T., Radulian, G., & Várkonyi, T. T. (2026) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2026.1905393
New Therapeutics for Diabetes Using Incretin Hormone
Oh, S. (2011) · The Korean Journal of Internal Medicine · Cited by 4
How best to control the lack of oxygen in the ischemic cardiomyocyte
Crea, F., & Lanza, G. A. (2009) · Dialogues in Cardiovascular Medicine
Metadata
- Authors
- Charbonnel, B., Karasik, A., Liu, J., Wu, M., Meininger, G., & for the Sitagliptin Study 020 Group
- Affiliations
- Centre Hospitalier Universitaire de Nantes (FR)
- Sheba Medical Center (IL)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2006-12-01
- Volume
- 29
- Issue
- 12
- Pages
- 2638-2643
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2171512247
- Cited by
- 790
- References
- 12
- Citations by year
- 2026: 7 · 2025: 10 · 2024: 7 · 2023: 9 · 2022: 10 · 2021: 19 · 2020: 19 · 2019: 15 · 2018: 12 · 2017: 27 · 2016: 29 · 2015: 39 · 2014: 47 · 2013: 48 · 2012: 47
- FWCI
- 60.45
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- sitagliptin, DPP-4 inhibitors, metformin, type 2 diabetes, inadequate glycemic control, HbA1c, pioglitazone, insulin sensitivity, beta-cell function, hypoglycemia, gastrointestinal adverse effects, body weight
- MeSH terms
- Sitagliptin Phosphate, Adolescent, Adult, Aged, Blood Glucose, Diabetes Mellitus, Type 2, Drug Therapy, Combination, Female, Glycoproteins, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Insulin, Male, Metformin, Middle Aged, Placebos, Proinsulin, Protease Inhibitors, Pyrazines, Triazoles, Single-Blind Method, Dipeptidyl Peptidase 4, Dipeptidyl-Peptidase IV Inhibitors, Adenosine Deaminase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.